

## CURRICULUM VITAE

**Jose Tomas Zaglul, M.D.**  
Florida Clinical Research Center, LLC  
3914 State Road 64 East  
Bradenton, FL 34208  
941-747-7900  
jzaglul@flcrc.com

### CONTACT INFORMATION:

Site Selection and Information:  
Bobbie Theodore, Site Liaison  
Tel. (866) 669-0234  
Fax (208) 575-3169  
Email: clinicaltrials@btheodore.com

### AFFILIATIONS:

Manatee Glens Corporation  
Bradenton, FL

Florida Clinical Research Center, LLC.  
Bradenton, FL

### MEDICAL EDUCATION:

1986 Doctor of Medicine  
Universidad Autonoma de Santo Domingo Medical School, Santo Domingo, Dominican Republic

1986-1989 Post-Graduate Training in Psychiatry  
Universidad Complutense de Madrid, Madrid, Spain

1989-1993 Residency in Psychiatry  
University of South Florida College of Medicine, Tampa, Florida

1993-1995 Fellowship in Child Psychiatry  
University of South Florida College of Medicine, Tampa, Florida

### CERTIFICATION:

American Board of Child and Adolescent Psychiatry, September 1996

American Board of Psychiatry and Neurology, June 1995

**LICENSURE:**

Florida Medical License: August 1991, # ME60726

Drug Enforcement Agency License: Number available on request

**PROFESSIONAL EXPERIENCE:**

*Investigator*, 2004-Present

Florida Clinical Research Center, LLC, Bradenton, Florida

*Chief Medical Officer*, 2006-Present

Manatee Glens Corporation, Bradenton, Florida

*Medical Director*, 2000-2006

Manatee Glens Corporation, Bradenton, Florida

*Acting Medical Director*, 1999-2000

Manatee Glens Corporation, Bradenton, Florida

*Clinical Medical Director*, 1996-1999

Manatee Glens Corporation, Bradenton, Florida

*Staff Psychiatrist*, 1995-Present

Manatee Glens Corporation, Bradenton, Florida

Mental Health Care, Inc., Tampa, Florida

*Staff Psychiatrist*, 1993-1995

University Psychiatry Center, Tampa, Florida

*Independent Contractor*, 1992-1993

**CLINICAL RESEARCH EXPERIENCE:**

Attention-Deficit Hyperactivity Disorder (ADHD) • Anxiety Disorders including Panic and OCD

Bipolar Disorders • Cognition • Depression • Fibromyalgia

Schizophrenia and Schizoaffective Disorder • Tourette's Disorder

**ADDITIONAL TREATMENT EXPERIENCE:**

Alzheimer's Disease • Pediatric Disorders

Substance Abuse and Other Addictions

**CLINICAL TRIAL EXPERIENCE:**

***ADHD***

A Randomized, Double-Blind, Placebo- and Active-Controlled, Parallel-Group, Multicenter Study of 3 Dosages of XXX in the Treatment of Adult Subjects With Attention-Deficit/Hyperactivity Disorder

A Placebo-controlled, Double-blind, Parallel-group, Individualized Dosing Study Optimizing Treatment of Adults with Attention Deficit Hyperactivity Disorder to an Effective Response with XXX

A Randomized, Multi-Center, Parallel Group, Dose Ranging Study to Evaluate the Safety and Tolerability of XXX in Children with Attention Deficit Hyperactivity Disorder (ADHD) and Persistent Serious Conduct Problems

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Dose-Ranging Study of the Safety and Efficacy of XXX in Children with Attention Deficit-Hyperactivity Disorder (ADHD)

The Long Term Safety and Tolerability of XXX in Children with Attention Deficit-Hyperactivity Disorder (ADHD): an Open-Label Extension

A Multi-Center, Double-Blind, Placebo-Controlled, Randomized, Parallel-Group Study to Investigate the Safety and Efficacy of XXX in Adults with Attention-Deficit/Hyperactivity Disorder.

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Study of the Safety and Efficacy of XXX in the Treatment of Children with Attention Deficit/Hyperactivity Disorder (ADHD)

Maintenance of Response After Open-Label Treatment of XXX in Adult Outpatients with Attention-Deficit/Hyperactivity Disorder (ADHD): A Placebo-Controlled, Randomized Withdrawal Study

A Phase III, Randomized, Double-Blind, Multi-Center, Parallel-Group, Placebo-Controlled, Forced-Dose Titration, Safety and Efficacy Study of XXX in Adolescents Aged 13-17 Years with Attention-Deficit/Hyperactivity Disorder (ADHD)

A Phase III, Open-Label, Extension, Multi-Center Safety and Efficacy Study of XXX in Adolescents Aged 13-17 Years with Attention-Deficit/Hyperactivity Disorder (ADHD)

An Open-Label, Chronic Exposure Evaluation of the Safety of XXX in the Treatment of Children and Adolescents with Attention Deficit Hyperactivity Disorder (ADHD)

**CLINICAL TRIAL EXPERIENCE (Continued):**

A Phase III Evaluation of the Efficacy and Safety of XXX as Add-on to Psychostimulant Medication vs. Psychostimulant Medication Alone in Treatment of Children and Adolescents with Attention Deficit Hyperactivity Disorder (ADHD)

A Phase III, Double-Blind, Randomized, Placebo-Controlled, Multi-Center, Dose Optimization Study Evaluating the Efficacy and Safety of XXX in Combination with Psychostimulants in Children and Adolescents Aged 6-17 Years with a Diagnosis of Attention-Deficit/Hyperactivity Disorder (ADHD)

***Bipolar Disorders***

A Double-Blind, Placebo-Controlled Study of XXX in Bipolar Depression

An Eight-Week, Multi-Center, Double-Blind, Randomized, Parallel-Group, Placebo-Controlled, Phase IV Study of the Efficacy and Safety of XXX Extended-Release as Mono-Therapy in Children and Adolescent Patients with Bipolar Depression

The Evaluation of XXX as an Add-On Treatment for Bipolar I Disorder in Children and Adolescents, 10 to 17 Years of Age

A Randomized, Double-Blind, Placebo-Controlled Study to Explore the Efficacy and Safety of XXX in the Prevention of Mood Episodes in Bipolar I Disorder, with Open-Label Extension

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Response, Multi-Center Study to Evaluate the Efficacy and Safety of Three Fixed Doses of Extended-Release XXX in the Treatment of Subjects with Acute Manic and Mixed Episodes Associated with Bipolar I Disorder

A Randomized, Double-Blind, Active- and Placebo-Controlled, Parallel-Group, Multi-Center Study to Evaluate the Efficacy and Safety of Flexibly-Dosed Extended-Release XXX Compared with Flexibly-Dosed XXX and Placebo in the Treatment of Acute Manic and Mixed Episodes Associated with Bipolar I Disorder.

A Phase IIIb, Multi-Center, Double-Blind, Parallel-Group, Two-Phase Trial (Three Week Fixed-Dose Placebo and Active Control Phase Followed By a Nine Week Flexible Dose Active Control Phase with XXX as a Control) Evaluating the Safety and Efficacy of XXX in Subjects with Bipolar I Disorder Experiencing an Acute Manic or Mixed Episode

A Phase III, Randomized, Placebo-Controlled, Double-Blind Trial Evaluating the Safety and Efficacy of Sublingual XXX vs. XXX and Placebo in Inpatients with an Acute Manic Episode

A Double-Blind, Nine-Week Extension Study Evaluating the Safety and Maintenance of Effect of XXX vs. XXX in the Treatment of Subjects with Acute Mania

**CLINICAL TRIAL EXPERIENCE (Continued):**

A Double-Blind, 40-Week Continuation Study Evaluating the Safety of XXX and XXX on the Treatment of Subjects with Acute Mania

A Phase III, Four-Week, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Multi-Center, Efficacy and Safety Study of XXX in Bipolar I Disorder Subjects with Acute Symptoms of Mania

A Multi-Center, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of XXX for the Treatment of Patients with Bipolar I Disorder Suffering Acute Manic or Mixed Episodes.

A Phase III, Flexible-Dose, Open-Label Continuation Trial Evaluating the Safety and Efficacy of XXX in Subjects with Bipolar I Disorder Completing Trial XXX for the Treatment of an Acute Manic or Mixed Episode

A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study of XXX Mono-Therapy in the Treatment of Acutely Manic Patients with Bipolar I Disorder

A Multi-Center, Double-Blind, Randomized, Parallel-Group, Placebo-Controlled, Phase III Study of the Efficacy and Safety of XXX Sustained-Release as Mono-Therapy in Adult Patients with Acute Bipolar Mania.

***Depression***

A 52-Week, Multi-center, Open-Label Study of the Safety and Tolerability of Sublingual Tablets in Patients with Major Depressive Disorder (MDD)

A Phase II, Multi-center, Randomized, Double-blind, Parallel-group, Placebo-controlled Exploratory Efficacy and Safety Study of XXX in Adults 18-55 years with Major Depressive Disorder (MDD) as Augmentation Therapy to an Antidepressant

A Double-Blind, Efficacy and Safety Study of XXX versus Placebo in the Treatment of Children and Adolescents with Major Depressive Disorder

A Phase IIa, Multi-Center, Randomized, Double-Blind, Double-Dummy, and Placebo- and Active-Controlled Study to Investigate the Safety and Efficacy of XXX Administered to Subjects with Major Depressive Disorder.

An XXX vs. Placebo in Patients with Major Depressive Disorder (MDD): Assessment of Energy and Vitality in MDD

A Double-Blind, Randomized, Placebo-Controlled Study Examining, the Safety, Efficacy, and Tolerability of XXX in Subjects with Major Depressive Disorder (Including Atypical and Melancholic Features).

**CLINICAL TRIAL EXPERIENCE (Continued):**

A Double-Blind, Randomized, Placebo Controlled, Multi-Center Study Examining the Efficacy and Safety of XXX in Subjects with Generalized Anxiety Disorder

A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Active-Referenced, Fixed-Dose Study Comparing the Efficacy and Safety of Two Doses of XXX in Acute Treatment of Adults with Major Depressive Disorder

A Long-Term, Open-Label, Flexible-Dose, Extension Study Evaluating the Safety and Tolerability of XXX in Subjects with Major Depressive Disorder

A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Fixed-Dose Study Comparing the Efficacy and Safety of a Single Dose of XXX in Acute Treatment of Adults with Generalized Anxiety Disorder

A Randomized, Double-Blind, Placebo Controlled Study Assessing the Efficacy and Safety of XXX and Evaluating Genetic Biomarkers Associated with Treatment Response in Patients with Major Depressive Disorder

A Double-Blind Study of XXX MR in Adult Patients with Major Depressive Disorder

A Long-Term, Open-Label Extension Study of XXX in Adult Patients with Major Depressive Disorder

***Schizophrenia and Schizoaffective Disorder***

A Phase II, 6-Week, Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Oral XXX Once Daily and XXX Once Daily for Treatment of Hospitalized Adult Patients with Acute Schizophrenia

A Six-Week, Multi-Center, Double-Blind, Double-Dummy, Randomized Comparison of the Efficacy and Safety of Sustained-Release Formulation XXX and Placebo in the Treatment of Acutely Ill Patients with Schizophrenia

An XXX vs. XXX in the Treatment of Acutely Ill Patients with Schizophrenia

A Double-Blind Randomized Study Comparing XXX with Placebo in the Treatment of Patients with Schizophrenia

An Open-Label Study of XXX in Patients with Schizophrenia or Schizoaffective Disorder

A Double-Blind Placebo-Controlled Evaluation of the Safety and Efficacy of XXX in the Acute Exacerbation of Schizophrenia

**CLINICAL TRIAL EXPERIENCE (Continued):**

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Two Dosages of XXX ER in the Treatment of Subjects with Schizoaffective Disorder

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of XXX ER Compared to XXX in Subjects with an Acute Exacerbation Schizophrenia

A Multi-Center, Randomized, Double-Blind, Fixed-Dose, Six-Week Trial of the Efficacy and Safety of XXX Compared with Placebo Using XXX Positive Control in Subjects with an Acute Exacerbation of Schizophrenia

A Randomized, Double-Blind, Placebo- and XXX-Controlled, Multi-Center Study to Evaluate the Efficacy, Safety and Tolerability of XXX Given B.I.D. for 28 Days to Schizophrenic Patients in Acute Exacerbation Followed by a Long-Term Treatment Phase

A Multi-Center, Double-Blind, Randomized, Placebo-Controlled, Study to Evaluate the Long-Term Efficacy, Safety and Tolerability of an Intramuscular Depot Formulation of XXX in Patients with Schizophrenia

A 52-Week, Multi-Center, Open-Label Study to Evaluate the Effectiveness of XXX Intramuscular Depot as Maintenance Treatment in Patients with Schizophrenia

A Six-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Center, Phase II Study of the Efficacy and Safety of XXX in Acutely Psychotic Subjects with Schizophrenia

A Phase III Randomized, Placebo-Controlled, Clinical Trial to Study the Safety and Efficacy of Three Doses of XXX in Acutely Psychotic Patients with Schizophrenia.

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Study to Evaluate the Efficacy and Safety of Two Fixed Dosages of Extended Release XXX in the Treatment of Subjects with Schizophrenia

A Phase III Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Clinical Trial to Study the Efficacy and Safety of Two Doses of XXX in Acutely Psychotic Subjects with Schizophrenia

An Evaluation of the Safety and Efficacy of XXX in the Acute Exacerbation of Schizophrenia

A Proof of Concept, Multi-Center, Randomized, Double-Blind, Parallel, Placebo-Controlled Study of XXX Sustained Release (SR) vs. Placebo in the Prevention of Weight Gain Associated with XXX Therapy for Psychosis

**CLINICAL TRIAL EXPERIENCE (Continued):**

***Other Indications***

A Multi-Center, Double-Blind, Flexible-Dose, Long-Term Extension Trial of the Safety and Maintenance of Effect of XXX Using XXX Positive Control in Subjects Who Complete Protocol XXX

A Randomized, Double-Blind, Placebo-Controlled, Flexible Dose Study to Evaluate Efficacy and Safety of XXX IR vs. Placebo for Six Weeks in Children and Adolescents (Aged 6-17 Inclusive) Diagnosed with Tourette's Disorder According to DSM IV Criteria

An Open-Label, Flexible Dose, Follow-Up Study to Evaluate Safety and Efficacy of Oral XXX for 24 Weeks in Children and Adolescents (Age 6-17 Years) Diagnosed with Tourette's Syndrome According to DSM-IV Criteria and Who Have Completed the Double-Blind Phase of Either Study XXX or XXX

A Flexible Dosed XXX vs. Placebo in the Treatment of Fibromyalgia